Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of HTI Vaccines in Early Treated HIV-1 Positive Individuals
NCT03204617Phase 1Completed
- Sponsor
- Aelix Therapeutics
- Start
- Jul 2017
- Primary completion
- Jul 2020
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DNA.HTI, MVA.HTI and ChAdOx1.HTI in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Aelix Therapeutics. Primary endpoints: Proportion of participants that develop Grade 3 or 4 local reactions at 32 weeks and Proportion of participants that develop Grade 3 or 4 systemic reactions at 32 weeks. Started Jul 2017; status: completed.
02
Drugs
DNA.HTIMVA.HTIChAdOx1.HTI
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03204617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03204617.